Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions

A poor prognosis of pancreatic ductal adenocarcinoma (PDAC) associated with chemoresistance has not changed for the past three decades. A multidisciplinary diagnosis followed by surgery and chemo(radiation)therapy is the main treatment approach. However, gemcitabine- and 5-fluorouracil-based therapi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yiyin, Yang, Chao, Cheng, He, Fan, Zhiyao, Huang, Qiuyi, Lu, Yu, Fan, Kun, Luo, Guopei, Jin, Kaizhou, Wang, Zhengshi, Liu, Chen, Yu, Xianjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5793409/
https://www.ncbi.nlm.nih.gov/pubmed/29386069
http://dx.doi.org/10.1186/s13045-017-0551-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5793409/
https://www.ncbi.nlm.nih.gov/pubmed/29386069
http://dx.doi.org/10.1186/s13045-017-0551-7

Ejemplares similares